Lais

The long-acting injectables (LAIs) are quickly developing through new drug delivery technologies that enhance stability, predictability, and bioavailability. New technologies like nanotechnology, model-informed drug development (MIDD), and bio-relevant dissolution testing are transforming the therapeutic landscape. Such technologies protect and permit the delivery of drugs continuously, with fewer dosing periods and increased compliance. With their potential, LAIs are promising in the treatment of chronic diseases and improvement of therapeutic outcomes, but are still restricted by the pharmacokinetic variability, safety issues, and regulatory issues. Hence, this review is an attempt to critically examine the reservoir effect and regulatory issues on long-acting injectables in psychiatric care. The existing overview was organized through the analysis of the progress in LAI technologies and the assessment of their possible use in the context of chronic diseases. Ideas were based on the emergent scientific literature on nanotechnology- based delivery, MIDD, and dissolution model, and the views regarding regulatory frameworks and stakeholder integration. The focus was put on patient compliance, individualized drug delivery platforms, and joint advances in biopharmaceutical studies. Literature showed that new methods such as nanotechnology, MIDD, and bio-relevant dissolution tests have enhanced the stability, predictability, and bioavailability of LAIs. Moreover, these innovations allow everyday delivery, lower dose and frequency of intake, and increase patient compliance with minimal side effects. Furthermore, LAIs have particularly great potential in the management of mental health conditions, infectious diseases, and hormonal disorders, in which patient convenience and long-term compliance are key factors to consider. It also includes the use of digital health tools and tailor-made dosing plans, which additionally enhance effectiveness, safety follow-up, and patient quality of life. LAIs have yet to be fully developed or used to their full potential due to their complicated pharmacokinetics, safety, and regulatory considerations. Dose-variable, safety in the long run, and idiosyncrasy are the most important uncertainties. These issues need to be tackled with a multi-stakeholder approach that would include government agencies, academic institutions, and pharmaceutical companies to come up with clear regulations, consistent assessment mechanisms, and evidence-based regulatory channels. The combination of interdisciplinary work, the use of real-life data, and sophisticated models is needed to create powerful and versatile LAI development strategies. To successfully implement LAIs into clinical practice, change the paradigms of therapeutic interventions, and benefit the general quality of life of patients, innovation and collaboration will be important in the future.